Skip to main content

biote Corp.

For the period ended Jun 30, 2026. Filed Aug 7, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 7, 2026

BTMD$1.08-2.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(in thousands) (Unaudited)

Six Months Ended June 30,
20262025
Operating Activities
Net income (loss)$(4,752)$19,764
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization1,9431,767
Bad debt (recovery) expense(771)962
Amortization of debt issuance costs378412
Provision for (recovery of) obsolete inventory(1,388)1,100
Non-cash lease expense340268
Non-cash interest on share repurchase liability—1,986
Share-based compensation expense3,7284,313
Gain from change in fair value of earnout liabilities(1,362)(8,856)
Loss on extinguishment of debt648—
Deferred income taxes3401,285
Changes in operating assets and liabilities:
Accounts receivable(171)(2,406)
Inventory2,1211,613
Other assets(1,116)(2,387)
Accounts payable(250)(1,950)
Deferred revenue(700)(60)
Accrued expenses4,171(3,910)
Payments pursuant to TRA(196)(93)
Operating lease liabilities(237)(255)
Net cash provided by operating activities2,72613,553
Investing Activities
Purchases of property and equipment(2,919)(3,439)
Purchases of capitalized software(873)(371)
Net cash used in investing activities(3,792)(3,810)
Financing Activities
Repurchases of Class A common stock(5,863)—
Borrowings on revolving loans12,500—
Repayments on revolving loans(17,500)—
Principal repayments on term loan(1,563)(3,125)
Borrowings on term loan125,000—
Extinguishment of debt(101,562)—
Debt issuance costs(3,431)—
Payments on repurchase liability(18,500)(25,081)
Proceeds from exercise of stock options—226
Issuance of stock under purchase plan4772
Distributions(1,021)(1,581)
Net cash used in financing activities(11,893)(29,489)
Effect of exchange rate changes on cash and cash equivalents45
Net decrease in cash and cash equivalents(12,955)(19,741)
Cash and cash equivalents at beginning of period24,12339,342
Cash and cash equivalents at end of period$11,168$19,601
Supplemental Disclosure of Cash Flow Information
Cash paid for interest$2,774$4,022
Cash paid for income taxes$1,726$2,508
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.